Literature DB >> 9783804

A rare variant translocation t(3;8)(q29;q22) without AML1/ETO fusion transcript in a case of oligoblastic leukemia.

Y Xue1, D Lu, Y Z Yuan, Y Guo, X Xie.   

Abstract

A 43-year-old man with oligoblastic leukemia and t(3;8) variant translocation is reported. At first he was classified as refractory anemia with excess of blasts in transformation according to the FAB criteria for myelodysplastic syndrome. Remission was obtained after intensive chemotherapy. After 8 months, a relapse occurred as overt M2 AML. At presentation chromosome study of bone marrow cells using R- and G-bandings revealed 45,X, -Y,t(3;8)(q29;q22) in 35 of the 42 metaphases analyzed and 46,XY,t(3;8) in one metaphase in addition to normal karyotype in the other six metaphases. However, RT-PCR assay showed no AML1/ETO fusion transcript. At relapse, a karyotype of 46, XY,t(3;8), deletion(4)(p14), add(7)(q32) was observed in all abnormal cells indicating a clonal karyotypic evolution. We believed that this case should be diagnosed as an early form of M2 AML initially. It may be the first case of oligoblastic leukemia with t(3;8) variant translocation. Further study is needed to elucidate its molecular entity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9783804     DOI: 10.1016/s0145-2126(98)00099-x

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Microgranular variant of acute promyelocytic leukemia with der(17) ins(17;15): A case report and review of the literature.

Authors:  Hongzai Guan; Jing Liu; Xiaofang Guo; Chunmei Wu; Huawei Yu
Journal:  Exp Ther Med       Date:  2015-06-18       Impact factor: 2.447

2.  A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain.

Authors:  Filomena Nozza; Gabriella Vona; Stefania Trino; Fiorella D'Auria; Francesco La Rocca; Vitina Grieco; Luciana Possidente; Luciana De Luca; Pellegrino Musto
Journal:  Mol Cytogenet       Date:  2019-07-05       Impact factor: 2.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.